- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03537573
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Non-Cancer Pain in Primary Care
The investigators will assess whether behavioral science-based interventions can "nudge" providers towards more evidence-based care for patients with acute non-cancer pain.
Aim 1) Among opioid naïve primary care patients with acute non-cancer pain, compare the effect of the provider-targeted behavioral interventions (opioid justification and provider comparison), individually and in combination, on initial opioid prescription, initial use of non-opioid management, and patient-reported pain and function.
Aim 2) Compare the effect of the 2 provider-targeted behavioral interventions, individually and in combination, on unsafe opioid prescribing and transition to chronic opioid therapy.
Aim 3) Assess provider satisfaction and experience with the provider-targeted behavioral interventions.
Hypotheses:
Aim 1, H1a: Compared with the guideline (usual care) alone, the addition of the opioid justification and provider comparison behavioral interventions will be associated with a decreased proportion of opioid prescription and increased proportion of non-opioid management at the initial outpatient visit for acute non-cancer pain.
Aim 1, H1b: Compared with usual care (guideline) alone, the addition of the opioid justification and provider comparison behavioral interventions will be associated with no difference in patient-reported pain, function, and satisfaction at 1, 6, and 12 months.
Aim 2, H2: Compared with the usual care (guideline), the addition of opioid justification and provider comparison behavioral interventions will be associated with a decreased proportion of patients receiving unsafe opioid therapy and a decreased proportion of patients transitioning to chronic opioid therapy.
Study Design: Pragmatic, cluster-randomized clinical trial in 48 primary care clinics.
Study Population: The patient population will be 19,855 opioid naïve adults who present to clinic with acute uncomplicated musculoskeletal pain or headache.
Primary and Secondary Outcomes: The primary outcome measures will be receipt of an initial opioid prescription and unsafe opioid prescribing. Secondary outcomes will be non-opioid pain management, and, in 514 patients, patient-reported pain and function.
Analytic Plan: The investigators will test for differences in the primary and secondary outcomes among the 4 intervention groups.
Once completed, the project will provide evidence that health systems and other stakeholders need to implement interventions to prevent unsafe opioid prescribing.
Обзор исследования
Статус
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15213
- UPMC Community Medicine Incorporated
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Patient Participants
Inclusion Criteria:
- Age 18 years or older; ii) index outpatient encounter with International Classification of Disease (ICD)-10 code for acute neck, back, or other musculoskeletal and headache diagnosis ("acute" defined as no similar diagnosis in past 3 months).
Exclusion Criteria:
- Cancer diagnosis (other than non-melanoma skin cancer)
- Receipt of opioid prescription within 12 months of index outpatient encounter
- Providers
Inclusion Criteria:
- Primary care provider (MD, Doctor of Osteopathy (DO), Physician Assistant (PA), Nurse Practitioner (NP)) at participating practice
Exclusion Criteria:
- None
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Факторное присвоение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Активный компаратор: Usual Care/Guideline
The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
|
The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
|
Экспериментальный: Guideline + Opioid Justification (OJ)
Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition.
The provider will be notified that the justification provided will be visible in the Epic EHR.
The provider has the option of entering a justification or not.
If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank).
The provider does not need to enter a justification if they choose to cancel the opioid prescription.
|
The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition.
The provider will be notified that the justification provided will be visible in the Epic EHR.
The provider has the option of entering a justification or not.
If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank).
The provider does not need to enter a justification if they choose to cancel the opioid prescription.
|
Экспериментальный: Guideline + Provider Comparison (PC)
Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months).
Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain.
Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
|
The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (> 3 months).
Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain.
Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
|
Экспериментальный: Guideline + OJ + PC
This arm will include the guideline, opioid justification, and provider comparison described above.
|
The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy.
Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition.
The provider will be notified that the justification provided will be visible in the Epic EHR.
The provider has the option of entering a justification or not.
If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank).
The provider does not need to enter a justification if they choose to cancel the opioid prescription.
Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids or acute pain who transition to chronic opioid therapy (> 3 months).
Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions, unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain.
Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Initial Opioid Prescription
Временное ограничение: 1 day (assessed on day of initial qualifying clinic visit
|
Initial opioid prescription (yes/no) (Primary) (Hypothesis 1a).
Opioid prescription at qualifying clinic visit, measured via electronic health record (EHR).
|
1 day (assessed on day of initial qualifying clinic visit
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Initial non-opioid management
Временное ограничение: 1 day (assessed on day of initial qualifying clinic visit)
|
Initial non-opioid management (yes/no) (Secondary) (Hypothesis 1a).
Defined as order for any non-opioid management strategy at baseline (e.g., non-opioid medication, physical therapy, behavioral therapy), measured via EHR.
|
1 day (assessed on day of initial qualifying clinic visit)
|
Change in Patient Reported Pain and Function
Временное ограничение: Assessed at 1, 6, and 12 months after initial qualifying clinic visit
|
Change in Patient Reported Pain and Function (Secondary) (Hypothesis 1b).
Measured by the 3-item Pain/Enjoyment/General Activities (PEG) instrument in clinic at baseline and via brief web survey or telephone interview
|
Assessed at 1, 6, and 12 months after initial qualifying clinic visit
|
Unsafe opioid prescribing at 3 months
Временное ограничение: 3 months after initial qualifying clinic visit
|
Defined over the prior 3 months as any of: a) receipt of initial extended release/long-acting opioid for acute pain; b) > 100 morphine milligram equivalent dose per day; c) opioid prescription in patients with substance use disorder or concurrent benzodiazepine prescription.
|
3 months after initial qualifying clinic visit
|
Unsafe opioid prescribing at 6 months
Временное ограничение: 6 months after initial qualifying clinic visit
|
Defined over the prior 3 months as any of: a) receipt of initial extended release/long-acting opioid for acute pain; b) > 100 morphine milligram equivalent dose per day; c) opioid prescription in patients with substance use disorder or concurrent benzodiazepine prescription.
|
6 months after initial qualifying clinic visit
|
Unsafe opioid prescribing at 12 months
Временное ограничение: 12 months after initial qualifying clinic visit
|
Defined over the prior 3 months as any of: a) receipt of initial extended release/long-acting opioid for acute pain; b) > 100 morphine milligram equivalent dose per day; c) opioid prescription in patients with substance use disorder or concurrent benzodiazepine prescription.
|
12 months after initial qualifying clinic visit
|
Chronic opioid therapy at 3 months
Временное ограничение: 3 months after initial qualifying clinic visit
|
Chronic opioid therapy (Secondary) (Hypothesis 2).
Ongoing, chronic opioid therapy will be measured via EHR
|
3 months after initial qualifying clinic visit
|
Chronic opioid therapy at 6 months
Временное ограничение: 6 months after initial qualifying clinic visit
|
Chronic opioid therapy (Secondary) (Hypothesis 2).
Ongoing, chronic opioid therapy will be measured via EHR
|
6 months after initial qualifying clinic visit
|
Chronic opioid therapy at 12 months
Временное ограничение: 12 months after initial qualifying clinic visit
|
Chronic opioid therapy (Secondary) (Hypothesis 2).
Ongoing, chronic opioid therapy will be measured via EHR
|
12 months after initial qualifying clinic visit
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Kevin L Kraemer, MD, University of Pittsburgh
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Боль
- Неврологические проявления
- Заболевания опорно-двигательного аппарата
- Мышечные заболевания
- Головная боль
- Острая боль
- Скелетно-мышечная боль
- Физиологические эффекты лекарств
- Депрессанты центральной нервной системы
- Агенты периферической нервной системы
- Анальгетики
- Агенты сенсорной системы
- Наркотики
- Анальгетики, Опиоиды
Другие идентификационные номера исследования
- UOP-1609-36881
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Usual Care/Guideline
-
The University of Texas Health Science Center,...Еще не набираютПитание при беременности высокого рискаСоединенные Штаты
-
University of MichiganAgency for Healthcare Research and Quality (AHRQ)Завершенный
-
Chung Shan Medical UniversityЗавершенныйОпекун | Пациент с инсультомТайвань
-
Johnson & Johnson Vision Care, Inc.ЗавершенныйОстрота зрения, биомикроскопия с щелевой лампой (оценка окрашивания роговицы)Соединенные Штаты
-
University of AlbertaUniversity Hospital FoundationЗавершенныйМерцательная аритмияКанада
-
New York UniversityIndiana University; Moi UniversityЗавершенный
-
Brigham and Women's HospitalAgency for Healthcare Research and Quality (AHRQ)Еще не набираютСердечная недостаточность | Сахарный диабет | Диабет | Хронические заболевания почек | Хроническая сердечная недостаточность
-
Institute of Mental Health, SingaporeNational Healthcare Group, SingaporeРекрутингСлабоумие | Бремя воспитателя | Цифровое здоровьеСингапур
-
University Health Network, TorontoРекрутингЛимфома | Лимфопролиферативные заболевания | Рак молочной железы Стадия I | Рак молочной железы Стадия II | Колоректальный рак II стадии | Колоректальный рак III стадии | Рак молочной железы Стадия III | Колоректальный рак I стадии | Рак головы и шеи III стадия | Рак молочной железы, стадия 0 | Рак головы... и другие заболеванияКанада
-
Emory UniversityFoundation for Physical Therapy, Inc.ЗавершенныйИнсультСоединенные Штаты